Executive Summary: Valuing an artificial intelligence company requires more than applying a standard revenue or EBITDA multiple. Investors and buyers look closely at recurring revenue, model differentiation, proprietary data assets, compute intensity, customer retention, and the sustainability of growth. Traditional discounted cash flow analysis still matters, but it must be adjusted for fast-changing margins, heavy […]
Electronic health record and health IT software companies are valued differently than traditional service businesses because a large portion of their worth comes from recurring revenue quality, customer retention, and the difficulty of replacing the platform. For Dallas business owners, understanding how annual recurring revenue (ARR), net revenue retention (NRR), implementation stickiness, and switching cost […]
AI-powered diagnostics companies can produce valuation outcomes that look very different from those of traditional healthcare services businesses. Their worth is often driven less by current earnings alone and more by regulatory milestones, clinical validation, recurring licensing revenue, data rights, and the degree to which payors and health systems are willing to adopt the product. […]
Executive Summary. Revenue Cycle Management (RCM) software companies are often valued on more than current earnings because their economics are shaped by recurring revenue, high retention, and deep workflow integration. For Dallas business owners, understanding metrics like revenue per provider, claim success rates, and net revenue retention (NRR) is essential because these indicators directly influence […]
Executive Summary: Telehealth platform valuation depends on more than headline revenue growth. Buyers and investors focus on patient visit volume, revenue per visit, payer contract penetration, and the durability of retention after the pandemic-era surge in virtual care. A credible valuation also considers reimbursement stability, customer concentration, normalized EBITDA, and recurring revenue quality. For Dallas […]
Healthtech business valuation is the process of estimating what a digital health company is worth by analyzing the revenue quality, patient engagement, clinical effectiveness, and regulatory position that drive its future cash flow. For Dallas business owners, investors, and advisors, this matters because digital health businesses often look very different from traditional service companies or […]
Executive summary: InsurTech valuations depend less on headline revenue and more on the quality and durability of that revenue stream. For Dallas business owners, investors, and advisors, the most important metrics include loss ratio, combined ratio, premium growth, retention, and the structure of embedded insurance distribution. Together, these indicators help determine whether an InsurTech company […]
Buy-now-pay-later, or BNPL, businesses have moved from being valued on growth narratives alone to being judged on the quality of that growth. For Dallas business owners, investors, and advisors evaluating a BNPL platform, the core question is no longer how fast gross merchandise volume (GMV) is rising, but whether that revenue is translating into durable, […]
Executive Summary: Neobank valuation is materially different from traditional bank valuation because investors are not primarily pricing book value and legacy balance sheet assets. Instead, they focus on the economics of each customer, including deposits per user, customer acquisition cost (CAC), revenue per account, retention, and the company’s path to profitability. For Dallas business owners, […]
Payment processing companies are valued using a blend of transaction economics, software metrics, and risk analysis. For Dallas business owners, the most important drivers are total payment volume (TPV), take rate, gross margin, and churn. These metrics determine how much revenue a processor can generate from each dollar of volume, how efficiently that revenue converts […]
- 1
- 2